Chunghwa Telecom Co (中華電信) said Apple Inc’s iPhone will hit its stores on Dec. 13, the latest effort by the nation’s biggest phone company to boost revenues amid declining mobile voice business.
Chunghwa Telecom will be the first local telecom operator to sell the iPhone in Taiwan, which has lagged behind other Asian markets such as India and Philippines in selling the smartphone.
Chunghwa Telecom said it was in talks with HTC Corp (宏達電), which makes the world’s first handset running Google Inc’s Android system, to offer second-generation G phones as well.
“The sale of the iPhone certainly will help boost our data revenues as the packages cover a wide range of data transmission services such as push e-mails,” Chunghwa Telecom spokesman Shih Mu-piao (石木標) said.
“Our average revenue per user [ARPU] from iPhone users may be more than NT$1,500 [US$45], compared with NT$1,100 ARPU from 3G subscribers,” Shih said.
Data services accounts for 10 percent of Chunghwa Telecom’s overall mobile revenues of NT$18.29 billion in the third quarter.
The company said it would sell iPhones exclusively for an unspecified period, with a two-year service contract carrying a minimal month fee of NT$1,049.
To get a free iPhone with 8GB memory space, people will have to sign a two-year contract with a monthly charge of NT$2,549. Or they can buy the phone from Chunghwa Telecom for at least NT$26,600 and get a prepaid number.
“We are targeting gift shoppers during Christmas and Lunar New Year holidays,” vice president Lin Jen-hon (林仁紅) said.
Chunghwa Telecom aims to sell 50,000 iPhones by March, Lin said.
However, officials admitted that this might not be the best time to be launching the iPhone because this could be the worst shopping season in recent years.
Chunghwa Telecom will begin taking orders for its iPhones today. The presale will last to Dec 10.
Share prices of Chunghwa Telecom rose 0.57 percent to NT$52.5, better than the broader market’s 0.15 percent gain yesterday.
Just a few years ago, the millennial generation — generally defined as those born from the early 1980s through the mid-1990s — was synonymous with youthful rebellion. However, now, as the millennials ease into early middle age, they are finding their path out of their parents’ basement to be a lot harder than it was for earlier generations. The fundamental problem is that millennials are not building wealth. The wealth of the median US household headed by someone 35 or younger has actually shrunk in inflation-adjusted terms since the mid-2000s, even as the wealth of older Americans has continued to grow. An
Apple Inc’s decision to stop using Intel Corp processors in its Mac computers and switching to its own chips might benefit Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) and boost Taiwan’s high-tech exports, Australia and New Zealand Banking Group (ANZ) said in a note on Tuesday. The US tech giant announced the “Apple silicon” initiative at its annual Worldwide Developers’ Conference, which started on Monday. The company said the first Mac powered by its own chips would debut by the end of this year and all product lines might shift to the new architecture in the next two years. TSMC is likely to
Gogoro Inc (睿能創意) yesterday launched its first electric bicycle, the Gogoro Eeyo 1, in Taiwan, after unveiling the bike in New York in late May and in France on Tuesday. The company said it would also introduce the series in other European countries such as Germany and the Netherlands. The “Eeyo project” is the fourth of Gogoro’s eight projects that concentrate on smart transportation, which includes Gogoro’s electric scooter, battery swap system and electric scooter sharing service, company founder and chief executive officer Horace Luke (陸學森) told a media briefing in Taipei. “There are various types of city commuters. We will not
EXPERIMENTAL DRUG: While news about a COVID-19 vaccine is more eye-catching, developing a treatment would be more viable, the Senhwa boss said Senhwa Biosciences Inc (生華科) aims to raise NT$1.5 billion (US$50.57 million) by issuing 15 million new common shares in the third quarter of this year to fund the research of new drugs, including the experimental drug Silmitasertib for the treatment of COVID-19, the company said on Monday. That would be the firm’s largest fundraising effort after it raised more than NT$1.4 billion from an initial public offering on the Taipei Exchange (TPEX) in April 2017, chief financial officer Sarah Chang (張小萍) told the Taipei Times by telephone. The price of the new shares would depend on the firm’s average share price